Drugs / nula-cel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04819841 | Nov 2021 → Dec 2026 expected | sickle cell disease | Kamau Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nula-cel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04819841 ↗ |
| Action | Restore | “nula-cel Drug Product is a human autologous CRISPR-Cas9 edited and sickle mutation-corrected HSPC product.” NCT04819841 ↗ |
| Modality | Cell therapy | “nula-cel Drug Product is a human autologous CRISPR-Cas9 edited and sickle mutation-corrected HSPC product.” NCT04819841 ↗ |
| Route | Intravenous | “via IV infusion” NCT04819841 ↗ |